AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00683527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemental iron
Description: Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
Study NCT03291535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connected-device
Description: This intervention will allow patients to upload blood pressure data automatically from a blood pressure cuff into the electronic health record.
Study NCT03291535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: This intervention will consist of usual clinical care as determined by the clinical pharmacist.
Study NCT03297047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combi cast
Description: upper arm or forearm combi cast
Study NCT03297047 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: combi cast
Description: upper arm or forearm combi cast
Study NCT02085460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02085460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Rebamipide liquid
Study NCT02085460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Rebamipide liquid
Study NCT00758017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture 1
Description: Application of individualised acupuncture
Study NCT00758017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture 2
Description: Application of standardised acupuncture
Study NCT01146769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise
Description: Pelvic floor strengthening exercise
Study NCT00739921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal swab under endoscopic guidance
Description: After the application of pontocaine and neosynephrine spray, the following will be done:~* A small sponge applicator will be used to swab the inside of your mouth for saliva collection~* A blood sample (6cc - one tube) will be collected~* A small brush applicator called a cytology brush and an instrument called an endoscope will be used to swab the inside of your nose (middle meatus)~* Subjects will be asked to complete 2 standard quality of life questionnaires regarding how much your symptoms bother you~* You will be asked to bring in a vacuum cleaner bag from home at a follow-up appointment which will be swabbed as well~The samples will be refrigerated and analyzed using PCR to detect and speciate fungus.
Study NCT01615146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion
Description: Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.~Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is \< 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded.
Study NCT01615146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.~Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is \< 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded.
Study NCT01680341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.
Study NCT01680341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
Study NCT00169182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL
Description: 75 mg/m 2 on day 1
Study NCT00169182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m 2 on day 1
Study NCT00169182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m 2 on day 1
Study NCT00169182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluoro-3-Pyridinecarboxylic Acid
Description: 750 mg/m 2 by 24-hour continuous infusion for 5 days
Study NCT00169182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoro-3-Pyridinecarboxylic Acid
Description: 750 mg/m 2 by 24-hour continuous infusion for 5 days
Study NCT03727438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Self CBTI
Description: The Tele-Self CBTI intervention is comprised of two treatment components: 1) self-directed treatment via weekly readings from a treatment manual, and 2) weekly telephone-based nurse support contacts across a 8 week intervention period. Participants have 8 weeks to complete 6 study-related phone calls
Study NCT03868423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: 90 mg orally QD for 7 days followed by 180 mg orally QD continuously thereafter. One cycle of therapy will consist of 28 days of treatment.
Study NCT03868423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03868423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03868423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04141748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symphonie Aqua SystemTM
Description: a water filled cylinder that can be pressurized around the residual limb to support body weight
Study NCT04141748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Casting
Description: plaster of Paris or fiberglass bandages are wrapped around the residual limb
Study NCT01803009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient views NCI CRC RAT
Study NCT01803009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: View presentation regarding current chance of having an advanced adenoma
Study NCT02546609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu-Met-Sil 0.5
Description: NS-0200 low dose
Study NCT02546609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leu-Met-Sil 1.0
Description: NS-200 high dose
Study NCT02546609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02905461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive text messages
Study NCT02905461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Text messages not about contraception
Study NCT05177393 — intervention group
Intervention type: OTHER
Intervention: Assessment of patient-reported outcomes (PROs)
Description: Questionnaires will be administered to participants
Study NCT03136887 — intervention group
Intervention type: DEVICE
Intervention: JOURNEY II XR Total Knee System
Description: JOURNEY II XR Total Knee System
Study NCT03913455 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Guadecitabine
Description: Guadecitabine 30 mg/m2 subcutaneously Days 1-5
Study NCT03913455 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin AUC 4 IV Day 5
Study NCT03614182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: physical training concurrent with cognitive training
Description: The P+C group will undertake standing balance, stepping, and treadmill walking training while concurrently perform cognitive tasks.
Study NCT03614182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: physical training followed by cognitive training
Description: The P-then-C group will train the same set of standing balance, stepping, and treadmill walking activities as the P+C group while followed by cognitive training later.
Study NCT03614182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: physical training without cognitive training
Description: The P group will only train the same set of standing balance, stepping, and treadmill walking activities as the other two groups.
Study NCT03913715 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ostomy Self-Management Training
Description: Ostomy Self management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations
Study NCT03913715 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ostomy Self-Management Training
Description: Ostomy Self management Training group in which subject will learn using pouches and equipment, skincare, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for traveling and physical activity recommendations
Study NCT02893397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Monitor
Description: Wear a fitbit
Study NCT02893397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo supervised exercise sessions
Study NCT02973386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMRT combine with cisplatin concurrent chemotherapy
Description: Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.
Study NCT02973386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
Description: Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
Study NCT02250846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: egfr-TKI treatment
Study NCT01611714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit-feedback
Description: Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.
Study NCT01611714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the headache electronic charting template.
Study NCT01149096 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Donation
Description: Undergo bone marrow harvest
Study NCT01149096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Donation
Description: Undergo bone marrow harvest
Study NCT01149096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously
Study NCT01149096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01149096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT04701008 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: IV ketamine - 10mg bolus may be repeated repeated 2-3 times depending on clinical judgement
Study NCT03964727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously
Study NCT03939624 — intervention group
Intervention type: DRUG
Intervention: Sodium-glucose cotransporter 2 (SGLT2) inhibitors
Description: Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
Study NCT03939624 — intervention group
Intervention type: DRUG
Intervention: Dipeptidyl peptidase-4 (DPP-4) inhibitors
Description: Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
Study NCT00834977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine-benazepril 10 mg-20 mg capsules
Description: 1 x 10-20 mg
Study NCT00834977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrel® 10 mg-20 mg capsule
Description: 1 x 10-20 mg
Study NCT02254863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DUOC-01
Description: Intrathecal administration of DUOC-01
Study NCT04197934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - blood samples
Description: Undergo collection of blood samples
Study NCT04197934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - CSF samples
Description: Undergo collection of CSF samples
Study NCT04197934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04197934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR/EGFRvIII Inhibitor WSD0922-FU
Description: Given PO
Study NCT03727438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: The Health Education Control condition is comprised of two components: 1) weekly reading from a health education manual, and 2) weekly telephone-based nurse support contacts across a 8 week period. At the end of the study, participants in the Health Education arm will be offered assistance for their sleep complaints, as needed, through the Durham Behavioral Sleep Medicine clinic.
Study NCT00432666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin)
Description: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection
Study NCT00432666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02247557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome encapsulated BoNT-A
Description: Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
Study NCT04197934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04197934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study NCT01500733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI 32765
Description: 420 mg daily
Study NCT02101775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT02101775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02101775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02101775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02101775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02101775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02101775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02101775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT02101775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02101775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04007692 — intervention group
Intervention type: PROCEDURE
Intervention: Esophageal stent placement
Description: Exposure of interest is standard of care esophageal stent placement
Study NCT02247557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX 200U in normal saline
Description: BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
Study NCT02247557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (N/S) 50ml in single intravesical instillation
Study NCT03982355 — intervention group
Intervention type: DEVICE
Intervention: DRS probe
Description: The Oxygenation measurements of the novel diffuse reflectance spectroscopy probe
Study NCT02365649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Dosing
Study NCT02365649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-494
Description: Oral Dosing
Study NCT04421053 — intervention group
Intervention type: BEHAVIORAL
Intervention: prenatal care for women with GDM
Description: we conduct prenatal care for GDM pregnancies through both prenatal clinic and app.
Study NCT02226367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin hydrochloride
Description: study drug arm prazosin
Study NCT02226367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: study drug arm placebo
Study NCT03904394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Four sets of 7 minutes at 65% of VO2peak interspersed with 3 min of passive recovery
Study NCT03904394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Four sets of 7 minutes at 65% of VO2peak interspersed with 3 min of passive recovery
Study NCT03975010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal Patch
Description: This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7\~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal.
Study NCT04240210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symtuza
Description: The study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
Study NCT02227914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
Study NCT02227914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Study subjects will receive sorafenib tablets twice a day for Days 1-28
Study NCT02227914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Study subjects will receive sorafenib tablets twice a day for Days 1-28
Study NCT03366610 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional